G6PD Deficiency and Oxidative Hemolysis

G6PD deficiency is not just a footnote in a biochemistry textbook; it is the most common human enzyme defect, affecting hundreds of millions globally. Understanding this condition bridges foundational genetics, biochemistry, and clinical medicine, illustrating how a single molecular malfunction can lead to dramatic and episodic disease. For medical students and MCAT examinees, mastering this topic is essential, as it integrates core principles of X-linked inheritance, redox biochemistry, and the clinical art of identifying trigger-mediated pathology.

Inheritance and Molecular Basis: An X-Linked Defect

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive disorder. This inheritance pattern has critical implications for its epidemiology and presentation. Since males (XY) have only one X chromosome, a single defective allele is sufficient to cause the full deficiency. Females (XX) require two defective alleles for full expression, but due to X-inactivation (lyonization), heterozygous females can be clinically affected with variable severity depending on the pattern of inactivation in their hematopoietic cell lines. This explains why the condition is far more common and typically more severe in males.

The G6PD enzyme catalyzes the first and rate-limiting step of the hexose monophosphate shunt (HMP shunt), also known as the pentose phosphate pathway. Its primary role in red blood cells (RBCs) is not energy production but defense. The reaction converts glucose-6-phosphate to 6-phosphogluconolactone, and in the process, reduces NADP+ to NADPH. This seemingly simple exchange is the cornerstone of RBC oxidative defense, as NADPH is the essential reducing agent that maintains cellular glutathione in its reduced, active state (GSH).

The Protective Pathway and Its Failure

Mature RBCs are uniquely vulnerable to oxidative stress. They lack nuclei and mitochondria, rendering them incapable of synthesizing new proteins or generating energy via oxidative phosphorylation. Their primary cargo, hemoglobin, contains iron, which can catalyze the formation of damaging reactive oxygen species (ROS). The cell's entire defense hinges on the HMP shunt and the NADPH it produces.

Here’s the protection cascade: NADPH fuels the enzyme glutathione reductase, which keeps glutathione (GSH) reduced. Reduced glutathione is then used by glutathione peroxidase to neutralize hydrogen peroxide and organic peroxides, converting them to harmless water and alcohols. In G6PD deficiency, this entire system fails under oxidative load. Without adequate NADPH, glutathione remains oxidized (GSSG), and peroxides accumulate.

Unchecked peroxides cause oxidative damage to hemoglobin, leading to denaturation and precipitation within the RBC. These precipitates are called Heinz bodies. They attach to the RBC membrane, making it rigid. As the spleen attempts to pluck out these inclusions, pieces of the membrane are removed, forming bite cells (degmacytes) or blister cells. The resulting RBC is mechanically fragile and prematurely destroyed by macrophages in the spleen—a process termed extravascular hemolysis. In severe crises, intravascular hemolysis can also occur.

Triggers of Hemolytic Crisis: The Biochemical "Why"

Hemolysis in G6PD deficiency is episodic, not chronic. Crises are provoked by exposures that overwhelm the already compromised oxidative defense system. For the MCAT and clinical practice, categorizing these triggers is key.

1. Infections: This is the most common trigger. The oxidative burst from activated neutrophils during a systemic infection generates a flood of ROS that the G6PD-deficient RBC cannot handle.
2. Drugs: Numerous medications act as pro-oxidants. Classic examples include:

• Primaquine: The drug whose use first identified the deficiency.
• Sulfonamides (e.g., sulfamethoxazole).
• Nitrofurantoin.
• Dapsone.
• Methylene blue. (A critical pitfall: used to treat methemoglobinemia, but dangerous in G6PD-deficient patients).

1. Fava Beans: This specific trigger gives rise to the term "favism." Certain compounds in fava beans (divicine, isouramil) are potent inducers of oxidative stress, leading to severe, acute hemolysis in susceptible individuals, often children.
2. Other Chemicals: Naphthalene (mothballs) is a well-known household agent.

Clinical Presentation and Diagnostic Hallmarks

The presentation varies with the severity of the enzyme variant. The most common variant worldwide (G6PD A-) causes episodic acute hemolytic anemia. Patients present with the classic triad of jaundice (from unconjugated bilirubin), dark urine (from hemoglobinuria or urobilinogen), and fatigue, typically 24-72 hours after exposure to a trigger. Physical exam may reveal pallor and splenomegaly.

Diagnosis relies on a high index of suspicion based on clinical history and key lab findings:

• Complete Blood Count (CBC): Shows normocytic, normochromic anemia. Reticulocyte count is elevated as the bone marrow compensates, but there is often a lag of a few days.
• Peripheral Blood Smear: The microscopic view is diagnostic. You will see bite cells and possibly blister cells, evidence of the spleen's "pitting" of Heinz bodies. Heinz bodies themselves are not visible on a standard Wright-stained smear but require special staining (crystal violet).
• Other Labs: Elevated indirect bilirubin, elevated LDH, low haptoglobin (consumed by binding free hemoglobin).
• Definitive Test: G6PD enzyme activity assay. A critical timing note: Testing during an acute hemolytic episode can yield a falsely normal result because the oldest, most enzyme-deficient RBCs have been destroyed, and the circulating reticulocytes have higher enzyme activity. The test should be repeated several weeks after recovery.

Management, Implications, and MCAT Focus

Management is primarily preventive. Patients must be educated to avoid known triggers. During a hemolytic crisis, treatment is supportive: discontinue the offending agent, provide hydration, and consider transfusion in severe cases. Neonatal jaundice is a significant complication and requires phototherapy or exchange transfusion to prevent kernicterus.

From an MCAT perspective, focus on the integration:

• Biochemistry: Link the HMP shunt's role in NADPH production to the glutathione antioxidant system. Understand that this is the RBC's primary, non-enzymatic antioxidant pathway (contrast with catalase in peroxisomes).
• Genetics: Apply X-linked inheritance patterns to predict disease probability in pedigrees.
• Cell Biology: Connect oxidative damage to hemoglobin denaturation (Heinz bodies) and subsequent RBC morphology (bite cells) and destruction (splenic macrophages).

Common Pitfalls

1. Confusing the Inheritance: It is X-linked recessive, not autosomal. Male-to-male transmission does not occur. A father passes his Y chromosome to sons, not his X.
2. Misunderstanding the Chronicity: G6PD deficiency is typically an episodic hemolytic anemia, not a continuous one like sickle cell disease or thalassemia. The baseline CBC may be normal between crises.
3. Misidentifying the Defender: The direct protector against peroxide is glutathione peroxidase, not G6PD. G6PD provides the NADPH that recycles glutathione. The MCAT loves to test this two-enzyme cascade.
4. Poor Test Timing: Ordering a G6PD assay right in the middle of a hemolytic crisis is a classic clinical and exam trap. The reticulocytosis can mask the deficiency.

Summary

• G6PD deficiency is the most common human enzymopathy, inherited in an X-linked recessive pattern, making it most severe in males.
• The enzyme initiates the HMP shunt to produce NADPH, which is essential for maintaining reduced glutathione and protecting RBCs from oxidative stress.
• Hemolytic crises are triggered by infections, drugs (primaquine, sulfonamides), and fava beans, which generate oxidative damage.
• Oxidized hemoglobin denatures and forms Heinz bodies, leading to RBC membrane damage and the appearance of bite cells on peripheral smear, followed by extravascular hemolysis.
• Diagnosis hinges on clinical history, smear findings, and a G6PD assay performed after the hemolytic crisis resolves to avoid a falsely normal result. Management is centered on trigger avoidance and supportive care.